Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CFTR and chaperones: processing and degradation.

Margarida D Amaral1

  • 1Department of Chemistry and Biochemistry, Faculty of Sciences, University of Lisboa, Lisboa, Portugal. mdamaral@fc.ul.pt

Journal of Molecular Neuroscience : MN
|May 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of HE4 expression concerning epithelial-mesenchymal transition (EMT) in cystic fibrosis epithelial cells.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Author's Reply to Yang and Wang: "Personalized Medicine in Cystic Fibrosis: Characterization of Eight Rare CFTR Variants in Intestinal Organoids and Cellular Models".

Molecular diagnosis & therapy·2026
Same author

Comparison of the Effect of CFTR Modulators <i>elexacaftor</i>/<i>tezacaftor</i>/<i>ivacaftor</i> and <i>lumacaftor</i>/<i>ivacaftor</i> via Serum Human Epididymis Protein 4 Concentration in <i>p.Phe508del-CFTR</i> Homozygous Cystic Fibrosis Patients.

Journal of clinical medicine·2025
Same author

Personalized Medicine in Cystic Fibrosis: Characterization of Eight Rare CFTR Variants in Intestinal Organoids and Cellular Models.

Molecular diagnosis & therapy·2025
Same author

CFTR ion transport deficiency primes the epithelium for partial epithelial-mesenchymal transition in cystic fibrosis.

Frontiers in pharmacology·2025
Same author

N1303K (p.Asn1303Lys) variant: Expanding frontiers in the treatment of cystic fibrosis.

Respiratory medicine·2025
Same journal

MYH2 as a Potential Modifier of Clinical Severity in Facioscapulohumeral Muscular Dystrophy.

Journal of molecular neuroscience : MN·2026
Same journal

Notch Signaling Regulates the Neuroprotective Effects of hUCMSCs in a Mouse Model of Cerebral Ischemia.

Journal of molecular neuroscience : MN·2026
Same journal

Co-Administration of LPC and LPS Enhanced the Spinal Cord Vulnerability in a Mouse Model of Focal Demyelination.

Journal of molecular neuroscience : MN·2026
Same journal

Biomarker Based ARIA Stress Test: A Proposed Conceptual Framework for Dynamic Biomarker-Guided ARIA Risk Stratification in Anti-Amyloid Immunotherapy for Alzheimer's Disease.

Journal of molecular neuroscience : MN·2026
Same journal

The Association Between Alzheimer's Disease-Related Biomarkers And Parkinson's Disease Based On Single-Cell Sequencing Analysis Combined With Mendelian Randomization.

Journal of molecular neuroscience : MN·2026
Same journal

Integrated Bioinformatics and in vivo Validation Identify the MTRNR2L1/MTRNR2L10 Axis as a Candidate Regulator Associated with Cortical NLRP3 Inflammasome-Related Signaling in Experimental Epilepsy.

Journal of molecular neuroscience : MN·2026
See all related articles

Cystic fibrosis (CF) arises from mutations in the CF transmembrane conductance regulator (CFTR) protein. This study explores how molecular chaperones influence CFTR processing and degradation, impacting CF disease mechanisms.

Area of Science:

  • Molecular biology
  • Cellular biology
  • Genetics

Background:

  • Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene.
  • The most common CF mutation, F508del, results in misfolded CFTR protein that is retained in the endoplasmic reticulum (ER) and degraded.
  • Understanding CFTR processing and degradation is crucial for developing effective CF therapies.

Purpose of the Study:

  • To review current knowledge on the interaction between molecular chaperones and CFTR protein.
  • To discuss the role of chaperones in the processing and degradation pathways of CFTR.
  • To identify key cellular mechanisms and protein players involved in CFTR conformational changes and fate.

Main Methods:

  • Literature review of existing data on CFTR-chaperone interactions.

Related Experiment Videos

  • Analysis of studies on CFTR folding, quality control, and degradation pathways.
  • Discussion of emerging knowledge on CFTR membrane protein processing.

    • Main Results:

    • F508del-CFTR misfolding leads to its retention in the ER and subsequent proteasomal degradation.
    • Molecular chaperones, including Hsp70/Hdj-1 and calnexin, are involved in CFTR quality control.
    • Distinct conformations of wild-type CFTR (wt-CFTR) and mutant CFTR suggest differential processing pathways, though key regulatory factors remain elusive.

    Conclusions:

    • Molecular chaperones play a significant role in the cellular fate of CFTR, influencing its processing and degradation.
    • Further research is needed to identify the specific mechanisms and protein players that determine whether CFTR enters the secretory pathway or is degraded.
    • Elucidating these pathways could reveal novel therapeutic targets for cystic fibrosis.